A study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune system plays in determining the duration of patients’ remission from multiple myeloma.
Gene therapy that induces the body to create microRNA-22, or miR-22, a naturally occurring molecule, successfully treated mice with hepatocellular carcinoma in a study at the UC Davis Comprehensive Cancer Center. The miR-22 treatment also reduced liver inflammation and produced better survival outcomes compared to the FDA-approved liver cancer treatment lenvatinib.
Scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. In a paper published in the journal mBio, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus. In evaluating EBVaGC’s epigenetics—the series of biological signals associated with the genome that determines whether a given gene is expressed—the Tempera lab highlights a target that could advance as a future treatment for this type of cancer.
NIH is planning to release a comprehensive dataset that standardizes genomic, proteomic, imaging, and clinical data from individual studies of more than 1,000 tumors across 10 cancer types.
The Medicaid expansion under the Patient Protection and Affordable Care Act resulted in a 19% annual increase in Medicaid-insured cancer patients participating in publicly funded clinical trials, according to researchers from Fred Hutchinson Cancer Center, the SWOG Statistics and Data Management Center and Columbia University.
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those surgeries, but still opt for lower volume hospitals closer to home when their cancer is likely less complex, according to an analysis by health policy scientists at the University of Pittsburgh School of Public Health.
The phase III ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met its primary endpoint of disease-free survival at a prespecified interim analysis.
In a prespecified interim analysis of the phase III LITESPARK-005 trial, Welireg, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, showed a statistically significant and clinically meaningful improvement in progression-free survival compared to Afinitor (everolimus) in adult patients with advanced renal cell carcinoma that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor therapies.
Robotic technology available at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is enabling physicians to obtain tissue biopsies in previously hard-to-reach areas of the lung to test for cancer.
Rural women with cancer often receive financial support from within their communities and from formal organizations, but not all patients have equal access to this assistance, according to a study conducted by researchers at the University of Arkansas for Medical Sciences Office of Community Health & Research.
